Japan's Eisai Links With Anaeropharma Science For Cancer Agent Study
This article was originally published in PharmAsia News
Executive Summary
Japan's Eisai and Anaeropharma Science say they have reached research and licensing agreements for the use of a new cancer agent, APS001